Validations: Hold-Time Studies (Bulk, Intermediate & Cleaning)

Sampling Plans for Hold-Time: Attribute vs Variable Choices

Sampling Plans for Hold-Time: Attribute vs Variable Choices Sampling Plans for Hold-Time: Attribute vs Variable Choices In the pharmaceutical industry, rigorous validation processes are critical to ensuring product quality and compliance with regulatory standards. Among these processes are the sampling plans for hold-time studies, which play a vital role in determining the safety and efficacy of bulk and intermediate materials,…

Continue Reading Sampling Plans for Hold-Time: Attribute vs Variable Choices

Locations & Times: Building a Representative Sampling Matrix

Locations & Times: Building a Representative Sampling Matrix In the pharmaceutical industry, the significance of a robust sampling strategy cannot be overstated. A well-developed sampling matrix is essential for ensuring compliance with cGMP regulations and for maintaining the quality and safety of pharmaceutical products. This article will outline a systematic step-by-step guide to building a representative sampling matrix, focusing on…

Continue Reading Locations & Times: Building a Representative Sampling Matrix

Acceptance Criteria for Bulk/Intermediate Holds: Justifications

Acceptance Criteria for Bulk/Intermediate Holds: Justifications In the pharmaceutical industry, the management of bulk and intermediate holds plays a crucial role in maintaining the integrity of product quality. Compliance with regulations, including 21 CFR Part 211 in the US, is essential to ensure that microbial limits on products are adhered to. This article provides a comprehensive, step-by-step tutorial guide for…

Continue Reading Acceptance Criteria for Bulk/Intermediate Holds: Justifications

Worst-Case Definition for Bulk Hold Studies

Worst-Case Definition for Bulk Hold Studies The pharmaceutical industry must ensure the quality and safety of products through stringent validation processes, including hold-time studies for bulk and intermediate materials. This article presents an in-depth guide on defining worst-case scenarios for bulk hold studies, focusing on microbial limits, equipment hold time, and acceptance criteria. Understanding Bulk Hold Studies Bulk hold studies…

Continue Reading Worst-Case Definition for Bulk Hold Studies

Scaling Hold-Time from Pilot to Commercial

Scaling Hold-Time from Pilot to Commercial Hold-time studies are critical components of the pharmaceutical manufacturing process, particularly when ensuring compliance with regulatory expectations from bodies such as the FDA, EMA, and MHRA. These studies help establish and verify the appropriate hold times for bulk drug substances, intermediates, and clean or dirty equipment. This tutorial provides a detailed, step-by-step guide to…

Continue Reading Scaling Hold-Time from Pilot to Commercial

Designing Realistic Simulants for Hold Studies

Designing Realistic Simulants for Hold Studies The need for robust and scientifically sound hold studies has become increasingly critical in the pharmaceutical industry, particularly in the context of ensuring the quality and safety of drug products. This article provides a comprehensive, step-by-step tutorial for designing realistic simulants for hold studies, focusing on equipment hold time, bulk hold time, and intermediate…

Continue Reading Designing Realistic Simulants for Hold Studies

Micro vs Chemical Attributes in Hold Acceptance

Micro vs Chemical Attributes in Hold Acceptance The considerations surrounding hold times in pharmaceutical manufacturing encompass both microbiological and chemical attributes. Understanding how to structure hold time studies, especially in relation to bioburden and endotoxin levels, is vital for maintaining compliance with regulations set forth by organizations such as the FDA, EMA, and MHRA. This article lays out a structured,…

Continue Reading Micro vs Chemical Attributes in Hold Acceptance

Bridging Hold Data Across Lots and Sites

Bridging Hold Data Across Lots and Sites Bridging Hold Data Across Lots and Sites Introduction to Hold-Time Studies Hold-time studies are vital in the pharmaceutical manufacturing process, particularly for ensuring compliance with regulatory standards such as the FDA’s 21 CFR Part 211. These studies are essential in validating the bioburden and endotoxin limits during various stages of drug production. Understanding…

Continue Reading Bridging Hold Data Across Lots and Sites

POU Filters During Hold: Integrity and Dwell Times

POU Filters During Hold: Integrity and Dwell Times In the pharmaceutical industry, ensuring product quality and compliance with regulatory standards is paramount. The focus on bioburden, endotoxin levels, and microbial limits during hold times has gained significant attention. This article will provide a comprehensive, step-by-step guide on the integrity testing of Point of Use (POU) filters during hold times, including…

Continue Reading POU Filters During Hold: Integrity and Dwell Times

Endotoxin Control for WFI/PW During Hold

Endotoxin Control for WFI/PW During Hold Endotoxin Control for WFI/PW During Hold In the pharmaceutical industry, the control of endotoxins in Water for Injection (WFI) and Purified Water (PW) is an essential aspect of ensuring product quality and compliance with regulatory guidelines. This step-by-step guide will focus on endotoxin control during hold-times for bulk and intermediate pharmaceutical products, addressing topics…

Continue Reading Endotoxin Control for WFI/PW During Hold